NVIDIA
NVDA
Tesla
TSLA
Palantir
PLTR
4
Super Micro Computer
SMCI
5
Hims & Hers Health
HIMS
US Stock MarketDetailed Quotes
SER Serina Therapeutics
- 4.660
- -0.020-0.43%
Close Feb 25 16:00 ET
46.10MMarket Cap-77.67P/E (TTM)
4.890High4.650Low4.58KVolume4.780Open4.680Pre Close21.66KTurnover0.15%Turnover RatioLossP/E (Static)9.89MShares22.82552wk High-3.35P/B13.89MFloat Cap3.81052wk Low--Dividend TTM2.98MShs Float209.262Historical High--Div YieldTTM5.13%Amplitude3.810Historical Low4.734Avg Price1Lot Size
Serina Therapeutics News
Serina Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Venkatesan Jay
Serina Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Venkatesan Jay
Serina Therapeutics | 8-K: Current report
Serina Therapeutics | 4: Statement of changes in beneficial ownership of securities-10% Owner Juvenescence Ltd
Serina Therapeutics | 8-K: Current report
Serina Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director WILSON KAREN J
Serina Therapeutics | 3: Initial statement of beneficial ownership of securities-Director WILSON KAREN J
Serina Therapeutics | 8-K: Current report
Serina Therapeutics | 8-K: Current report
Serina Therapeutics | 8-K: Current report
Serina Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Bailey Gregory
Serina Therapeutics | 8-K: Current report
Serina Therapeutics | 8-K: Current report
Serina Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Juvenescence Limited(42.0%),JuvVentures (UK) Limited(41.3%)
Serina Therapeutics | 8-K: Current report
Serina Therapeutics | 424B3: Prospectus
Serina Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Broadwood Partners, L.P.(2.1%),Broadwood Capital, Inc.(2.1%), etc.
Serina Therapeutics | 8-K: Serina Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights
Serina Therapeutics | 10-Q: Quarterly report
Serina Therapeutics | ARS: Annual Report to Security Holders